Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Dose-response Pilot Study of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in Subjects With Anxiety Associated With Advanced-stage Cancer.

NCT00252174 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT00252174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00252174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Dose-response Pilot Study of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in Subjects With Anxiety Associated With Advanced-stage Cancer.
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2007
Completion date
March 31, 2011
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety disorder, cancer